Wealthspire Advisors LLC Sells 805 Shares of Zoetis Inc. (NYSE:ZTS)

Wealthspire Advisors LLC cut its position in Zoetis Inc. (NYSE:ZTS) by 11.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,265 shares of the company’s stock after selling 805 shares during the quarter. Wealthspire Advisors LLC’s holdings in Zoetis were worth $1,021,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the company. Fisher Funds Management LTD bought a new stake in Zoetis during the fourth quarter valued at $66,123,000. Pinnacle Financial Partners Inc raised its holdings in shares of Zoetis by 0.6% in the 4th quarter. Pinnacle Financial Partners Inc now owns 46,136 shares of the company’s stock valued at $7,520,000 after acquiring an additional 271 shares in the last quarter. Sigma Planning Corp raised its holdings in shares of Zoetis by 4.3% in the 4th quarter. Sigma Planning Corp now owns 3,367 shares of the company’s stock valued at $549,000 after acquiring an additional 140 shares in the last quarter. Oxbow Advisors LLC boosted its position in shares of Zoetis by 768.1% during the 4th quarter. Oxbow Advisors LLC now owns 27,284 shares of the company’s stock valued at $4,445,000 after acquiring an additional 24,141 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators grew its holdings in shares of Zoetis by 6.6% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock worth $170,000 after purchasing an additional 65 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

ZTS opened at $168.60 on Wednesday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The stock’s 50 day simple moving average is $166.26 and its 200 day simple moving average is $177.66. The firm has a market cap of $75.50 billion, a price-to-earnings ratio of 30.82, a PEG ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. As a group, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.19%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of recent analyst reports. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Piper Sandler reduced their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. Barclays lifted their price target on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Finally, StockNews.com lowered Zoetis from a “buy” rating to a “hold” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Zoetis presently has an average rating of “Buy” and an average target price of $215.40.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.